4269 studies found for:    "complement factor I deficiency" OR "Immunologic Deficiency Syndromes"
Show Display Options
Rank Status Study
1 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation
2 Completed A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinemia;   Hyper-IgM Syndrome;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex
3 Suspended Pharmacokinetics (PK) and Safety of Subgam®VF in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-Immunoglobulin M (IgM0Syndrome
Intervention: Biological: Subgam
4 Recruiting Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes
Conditions: Agammaglobulinemia;   Common Variable Immunodeficiency;   Immunologic Deficiency Syndrome
Intervention:
5 Recruiting Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Conditions: Lymphohistiocytosis, Hemophagocytic;   Common Variable Immunodeficiency;   Severe Combined Immunodeficiency
Intervention:
6 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
7 Completed
Has Results
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Conditions: Primary Immunodeficiency;   Common Variable Hypogammaglobulinemia;   X-linked Hypogammaglobulinemia;   Hypogammaglobulinemia;   Immunodeficiency With Hyper-IgM;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex (Intravenous immunoglobulin)
8 Recruiting Molecular and Clinical Studies of Primary Immunodeficiency Diseases
Condition: Immunologic Deficiency Syndrome
Intervention:
9 Terminated
Has Results
Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
Conditions: Severe Combined Immunodeficiency Disease;   Severe Primary Immunodeficiency Disorder;   Undefined T Cell Deficiency Disorder;   Wiskott-Aldrick Syndrome
Interventions: Biological: Campath -1H;   Drug: Fludarabine;   Biological: Anti-CD45;   Procedure: Stem cell infusion
10 Completed Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS);   Human Immunodeficiency Virus Infections
Interventions: Drug: Serostim®;   Drug: Placebo
11 Completed An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS);   Human Immunodeficiency Virus Infections
Intervention: Drug: Serostim®
12 Completed Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Conditions: Immunologic Deficiency Syndrome;   Agammaglobulinemia;   Severe Combined Immunodeficiency;   Wiskott-Aldrich Syndrome;   Common Variable Immunodeficiency
Interventions: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;   Drug: Dextrose, 5% in Water
13 Recruiting Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-IgM Syndrome
Interventions: Biological: Gammaplex (5%);   Biological: Gammaplex 10
14 Completed A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
Conditions: HIV Infections;   Immunologic Deficiency Syndromes;   Lymphoproliferative Disorders
Intervention: Drug: all-trans-retinoic acid with IFN-alpha2a
15 Recruiting Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
Condition: Primary Immune Deficiency Disorder
Intervention: Other: Immunoglobulin Therapy
16 Terminated Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
Condition: Immunologic Deficiency Syndromes
Intervention: Drug: Octagam 10%
17 Completed Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
Condition: Immunologic Deficiency Syndrome
Intervention: Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
18 Completed
Has Results
A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency
Condition: Immunologic Deficiency Syndrome
Intervention: Biological: Immune Globulin Intravenous (Human)
19 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
20 Completed
Has Results
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Condition: Primary Immune Deficiency Disorders (PIDD)
Intervention: Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years